
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
The agency has added a COVID-19 innovation resource page and an education resources page to its website.
To provide the public with information regarding COVID-19, FDA has created two web pages on its website: "Innovation to Respond to COVID-19" and "Educational Resources".
Source:






